Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) Consolidated Net Income: 2013-2024

Historic Consolidated Net Income for vTv Therapeutics (VTVT) over the last 12 years, with Dec 2024 value amounting to -$22.7 million.

  • vTv Therapeutics' Consolidated Net Income fell 77.14% to -$10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$28.4 million, marking a year-over-year decrease of 24.97%. This contributed to the annual value of -$22.7 million for FY2024, which is 12.56% up from last year.
  • Latest data reveals that vTv Therapeutics reported Consolidated Net Income of -$22.7 million as of FY2024, which was up 12.56% from -$26.0 million recorded in FY2023.
  • vTv Therapeutics' 5-year Consolidated Net Income high stood at -$12.8 million for FY2020, and its period low was -$26.0 million during FY2023.
  • Moreover, its 3-year median value for Consolidated Net Income was -$25.1 million (2022), whereas its average is -$24.6 million.
  • As far as peak fluctuations go, vTv Therapeutics' Consolidated Net Income spiked by 41.64% in 2020, and later crashed by 41.41% in 2022.
  • vTv Therapeutics' Consolidated Net Income (Yearly) stood at -$12.8 million in 2020, then crashed by 38.50% to -$17.7 million in 2021, then plummeted by 41.41% to -$25.1 million in 2022, then decreased by 3.56% to -$26.0 million in 2023, then climbed by 12.56% to -$22.7 million in 2024.